DBP International AB: Australian patent for Temodex / SI-053 is granted
Patent approval provides protection for the technology and the product in Australia until at least 2036.
"This is an important milestone in the development of SI-053 to get product patented and this is very good news for the company especially now prior starting clinical trials", comments Igor Lokot, CEO of DBP. - "We also have other applications pending for additional important markets."
More about Temodex/SI-053: Temodex, which is a locally acting formulation of temozolomide developed by RI PCP in Minsk, Belarus, is registered for marketing as the first-line treatment of glioblastoma within Belarus since 2014. Temodex was acquired by DBP in autumn 2015 and is now being prepared under the name SI-053 to pass through all the tests and trials required for registration within the EU and globally.
Video presentation: https://youtu.be/iweOQPq316o
This disclosure contains information that DBP is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 01-11-2022 08:30 CET.